Treatment with DA-1726 Shows No Evidence of Cardiovascular Changes On May 26, 2026, MetaVia, Inc. (NASDAQ: MTVA) announced the presentation of new Phase 1 data for DA-1726, the company’s oxyntomodulin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results